熱門資訊> 正文
联邦上诉法院考虑恢复肯芙的泰诺和自闭症案件
2025-11-17 23:12
- A U.S. appeals court is scheduled on Monday to hear arguments from attorneys representing individuals who are seeking to revive claims that use of Kenvue's (KVUE) painkiller Tylenol (acetaminophen) in pregnancy led to autism in children.
- Plaintiffs are using the the Trump administration's announcement in September linking Tylenol use in pregnancy to autism as the basis for the new push.
- If the Second U.S. Circuit Court of Appeals gives the green light for plaintiffs to proceed, Kenvue could face more than 500 lawsuits.
- A lower court quashed the lawsuits in March 2024, finding that the plaintiffs didn't provide "admissible evidence" about a relationship between Tylenol use in pregnancy and autism or ADHD in offspring.
- In October, Texas Attorney General Ken Paxton sued Kenvue, alleging the company failed to warn about the Tylenol in pregnancy and autism or ADHD in children link.
More on Kenvue
- The Merger Between Kimberly-Clark And Kenvue Clearly Favors One Party
- Kimberly-Clark: Can The Kenvue Acquisition Erase The Decade Of Disappointment?
- The Key Question Around The Kenvue/Kimberly-Clark Tie-Up
- Kenvue can pay $400M shareholder dividend, judge rules
- Oakmark U.S. Large Value Strategy buys TRGP, UNP; exits BLK, CNC and KVUE
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
